Skip to Content
Global News Select

Gilead Sciences Reports 16% Revenue Increase in 1Q Driven by Remdesivir Sales

By Maria Armental

 

Gilead Sciences Inc.'s revenue rose about 16% in the latest period, helped by sales of its antiviral drug remdesivir that is used to treat hospitalized Covid-19 patients.

Remdesivir, which sells under the brand name Veklury and has been widely used to treat hospitalized Covid-19 patients, brought in $1.46 million in sales in the March quarter, ahead of analysts' expectations, according to FactSet.

The World Health Organization has recommended against using remdesivir after concluding that there wasn't evidence that the drug reduced deaths or recovery times.

Sales of Gilead's other drugs were hurt by pandemic-related shutdowns.

Overall, first-quarter profit rose to $1.73 billion, from $1.55 billion a year earlier, while revenue rose to $6.42 billion.

Analysts surveyed by FactSet expected a profit of $2.35 billion on $6.74 billion in revenue.

Total product sales excluding Veklury, the company said, fell 11% to $4.9 billion.

In response to the Covid-19 case surge in India, now at the center of the worst coronavirus crisis, Gilead pledged to offer technical assistance to voluntary licensees to expand local production capacity of remdesivir and support additional manufacturing facilities as well as donate the active pharmaceutical ingredient. Gilead will also donate at least 450,000 vials of Veklury to the Indian government.

On Thursday, it maintained projections of $2 billion to $3 billion in Veklury sales and $23.7 billion to $25.1 billion in overall product sales for the year.

It now sees profit of $4.75 to $5.45 a share, compared with its earlier view of $5.25 to $5.95 a share, but maintained the projected adjusted profit range at $6.75 to $7.45 a share.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

April 29, 2021 16:35 ET (20:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.